Overview

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Status:
Completed

Trial end date:
2018-11-14

Target enrollment:

Participant gender:

Summary

In this phase I pilot study, it is planned to investigate the feasibility and safety of adding an interferon therapy to an preexisting imatinib treatment in patients with chronic phase chronic myeloid leukaemia. The participating patients have already reached a response during their imatinib therapy (CCyR) but have still a detectable disease (no molecular response MR 4.5 or better).

Phase:

Phase 1

Details

Lead Sponsor:

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborator:

AOP Orphan Pharmaceuticals AG

Treatments:

Imatinib Mesylate
Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b